Whitehawk Therapeutics, Inc.

WHWK

Healthcare Biotechnology

Whitehawk Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.1 million, down 72.5% from fiscal 2024.

Revenue
+33.5%
EPS
+73.7%
Free cash flow
+72.6%

Quarter to June 2026, against a year earlier

3.13 0.11 +3.64%
Market cap
$178.4M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
4/9
ROIC
0.00%
Net debt / EBITDA
1.3×
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
16.76 10.26 11.36 17.38
Net Debt/EBITDA
8.03 5.67 5.16 10.29
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.22) (0.28) (0.32) (0.18)
Book value per Share
2.27 2.20 1.68 2.21
Free Cash Flow
(15.38) (17.23) (22.21) (14.53)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026